Research Analysts Issue Forecasts for Genelux Q3 Earnings

Key Points

• Brookline Capital Management has adjusted its Q3 2025 earnings estimates for Genelux Corporation, lowering the expected earnings per share to ($0.21) from ($0.20).
• Despite the downward revision, Genelux recently reported Q2 earnings of ($0.20) per share, exceeding consensus estimates of ($0.22) by $0.02.
• As of now, the stock holds an average rating of "Buy" with a consensus target price of $17.75, although Benchmark has lowered its target price to $23.00.

Genelux Corporation (NASDAQ:GNLX - Free Report) - Stock analysts at Brookline Capital Management lowered their Q3 2025 earnings per share estimates for shares of Genelux in a report issued on Tuesday, August 12th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.21) per share for the quarter, down from their previous forecast of ($0.20). The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux's FY2025 earnings at ($0.82) EPS.

Genelux (NASDAQ:GNLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.02.

A number of other brokerages have also weighed in on GNLX. HC Wainwright reaffirmed a "buy" rating on shares of Genelux in a research note on Wednesday, July 23rd. Benchmark cut their price objective on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Genelux from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company's stock. Based on data from MarketBeat, Genelux has a consensus rating of "Buy" and a consensus price target of $17.75.

Genelux Price Performance

Genelux stock traded down $0.1130 during midday trading on Friday, reaching $3.3170. The company had a trading volume of 41,067 shares, compared to its average volume of 180,713. The company has a market capitalization of $125.28 million, a P/E ratio of -3.81 and a beta of -0.32. Genelux has a 12-month low of $1.95 and a 12-month high of $5.89. The firm's fifty day simple moving average is $3.21 and its 200-day simple moving average is $3.24.

Hedge Funds Weigh In On Genelux

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Woodward Diversified Capital LLC lifted its position in shares of Genelux by 21.7% during the 2nd quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company's stock worth $5,104,000 after purchasing an additional 317,173 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Genelux by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company's stock worth $915,000 after purchasing an additional 5,596 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Genelux during the 1st quarter worth $770,000. Heights Capital Management Inc. purchased a new stake in shares of Genelux during the 1st quarter worth $644,000. Finally, MAI Capital Management lifted its position in shares of Genelux by 66,161.3% during the 2nd quarter. MAI Capital Management now owns 236,553 shares of the company's stock worth $679,000 after purchasing an additional 236,196 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company's stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.